Neuropharm Group plc

This year, as well as last, the death of two horses at the recent UK Grand National race has led to a considerable amount of consternation amongst the horseracing, and even the general community. Inte

The recent outpouring of soul searching, introspection and discussion prompted by the parting editorial from Greg Smith, a now ex-Goldman Sachs investment banker, has had little linkage to the biotech

Neuropharm has recommended to its shareholders that its operations be wound up by way of voluntary liquidation. The UK company has struggled since last year when a Phase III study of NPL-2008 failed t

Neuropharm is considering voluntary liquidation and a return of cash to shareholders as attempts to secure a sale or merger of the company have yet to come to fruition. The speciality pharmaceutical c